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Abstract: The time required to reach a correct diagnosis is a key concern for rare disease (RD)
patients. Diagnostic delay can be intolerably long, often described as an “odyssey” and, for some,
a diagnosis may remain frustratingly elusive. The International Rare Disease Research Consortium
proposed, as ultimate goal for 2017–2027, to enable all people with a suspected RD to be diagnosed
within one year of presentation, if the disorder is known. Subsequently, unsolved cases would
enter a globally coordinated diagnostic and research pipeline. In-depth analysis of the genotype
through next generation sequencing, together with a standardized in-depth phenotype description
and sophisticated high-throughput approaches, have been applied as diagnostic tools to increase
the chance of a timely and accurate diagnosis. The success of this approach is evident in the
Orphanet database. From 2010 to March 2017 over 600 new RDs and roughly 3600 linked genes
have been described and identified. However, combination of -omics and phenotype data, as well
as international sharing of this information, has raised ethical concerns. Values to be assessed
include not only patient autonomy but also family implications, beneficence, non-maleficence, justice,
solidarity and reciprocity, which must be respected and promoted and, at the same time, balanced
among each other. In this work we suggest that, to maximize patients’ involvement in the search
for a diagnosis and identification of new causative genes, undiagnosed patients should have the
possibility to: (1) actively participate in the description of their phenotype; (2) choose the level of
visibility of their profile in matchmaking databases; (3) express their preferences regarding return of
new findings, in particular which level of Variant of Unknown Significance (VUS) significance should
be considered relevant to them. The quality of the relationship between individual patients and
physicians, and between the patient community and the scientific community, is critically important
for optimizing the use of available data and enabling international collaboration in order to provide
a diagnosis, and the attached support, to unsolved cases. The contribution of patients to collecting
and coding data comprehensively is critical for efficient use of data downstream of data collection.
Keywords: undiagnosed rare diseases; diagnostic odyssey; next generation sequencing; deep
phenotyping; genomic matchmaking; secondary findings; patient involvement
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1. Background
Making a diagnosis for a rare genetic disorder can be very challenging. Currently, 6000–8000
rare diseases (RDs) are known to the scientific community [1], with an additional 250–280 new
diseases described annually [2]. The most rare of these diseases are estimated to affect about
1/2,000,000 patients [3]. The time required to reach a correct diagnosis is one of the most important
problems for rare disease (RD) patients and, for some a definitive diagnosis may never be determined.
As outlined within the “International recommendations to address specific needs of undiagnosed rare
disease patients” there are two groups of undiagnosed patients [4]:
(1) ‘Not yet diagnosed’ refers to patients suffering from known conditions that should be diagnosed
but haven’t been as they have not been referred to the appropriate clinician or clinical center;
(2) ‘Undiagnosed’ (“Syndromes Without A Name” or SWAN) refers to patients for whom a diagnostic
test is not yet available since the disease has not been characterized and the cause(s) not
yet identified.
According to Black et al. the “diagnostic odyssey” of RD patients encompasses three different
periods: patient interval; primary care interval; and specialist care interval [5]. The length of the patient
interval may depend on the frequency and severity of presenting signs and symptoms, as well as on
a patient’s or carer’s capacity to recognize these. While a sign is objective evidence of a disease (such as
a skin rash), and can be detected by someone different from the individual affected, a symptom can
only be recognized by the individual themselves. Therefore, subjective symptoms, such as fatigue or
abdominal pain, may not be timely recognized by a healthcare professional.
The length of the primary care interval will depend, amongst other factors, on the time needed
by the General Practitioner (GP) to screen for common and simple diseases before considering more
complex and rare conditions, for which referral to a specialist is needed [6].
In both primary and specialized care, diagnostic delays and/or errors may occur for several
reasons: firstly, the physician may lack knowledge regarding the specific manifestations of the
condition or may not have performed the necessary and appropriate diagnostics tests. Secondly,
the patient may present with atypical symptoms and/or clinical manifestations for a known disorder;
with a combination of symptoms suggestive of multiple disorders, or even a novel, unreported disorder.
Thirdly, there may be instances in which a non-genetic risk factor is implicated, but not clearly
identified. For example, a rare syndrome associated with the use of a certain drug or with the exposition
to multifactorial environmental factors [7].
Furthermore, there may be a communication barrier between patient and physician. This is
evident in minors, where their age or disability prevents detailed expression of their symptoms,
such as fatigue or pain, especially when these do not appear to have an obvious medical cause.
Some delay is to be expected in the diagnosis of a rare disorder, however, this delay can be
intolerably long.
In a survey carried out by the European Organisation for Rare Diseases (EURORDIS) on
eight relatively “common” RDs (Crohn’s disease, cystic fibrosis, Duchenne muscular dystrophy,
Ehlers-Danlos syndrome, Marfan syndrome, Prader Willi syndrome, tuberous sclerosis, fragile X
syndrome), 25% of patients reported to have waited between 5 to 30 years for the correct diagnosis,
with the initial diagnosis being incorrect in 40% of cases [8]. Although exact statistics are not available,
the situation is likely worse for the rarest disorders. The impact of such an experience is immense for
the individual patient and his/her family, and incurs a cost to society.
Diagnostic delays prevent patients from accessing specialized healthcare and social services in
a timely manner. Periodical follow up appointments, that are standard practice for other severe and
chronic conditions such as cancer, are unavailable until a diagnosis has been made. This forces them
to rely upon their own finances and resources to gain access to the necessary services. A delay in
diagnosis also subjects the patient to useless visits and procedures, some of which are invasive and
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painful. Ultimately, delays prevents doctors initiating the right therapeutic regimen, if available, for
the patient’s specific condition.
The uncertainty regarding diagnosis also has psychological and social sequelae. Misunderstandings
in a patient’s social environment, a sense of isolation and even stigmatization of the patient or his/her
parents may have a profound and lasting effect on the undiagnosed patient in question.
To add to the biopsychosocial model, implications for reproductive choices should be taken into
account, as the absence of diagnosis prevents families from making informed decisions [9].
A delayed or missed diagnosis may create undue inequalities in comparison with other categories
of patients that can access diagnosis, and hence medical support, more readily. Therefore, we may
suggest that, whenever possible, there is a duty to pursue a timely and accurate diagnosis, or at
least guarantee access to care for patients where clinical observations are inconclusive with respect to
a specific codified diagnosis.
Several initiatives have been developed at the national and international level to approach the
problem of undiagnosed rare diseases.
In 2008, the U.S. National Institutes of Health (NIH) Undiagnosed Disease Program (UDP),
through the efforts of the National Human Genome Research Institute, the NIH Clinical Center,
the Office of Rare Diseases Research, and other NIH research institutes and centers, arose to provide
a diagnosis for individuals who had long sought one without success [10]. The success of the NIH
UDP led to an expansion of the program to other seven clinical research institutes across the USA.
Inspired by the US initiative and prompted by parents of undiagnosed children, the Undiagnosed
Diseases Network International (UDNI) was established in 2015 and currently includes Australia,
Canada, Japan, Israel, India, Japan, Korea, Sri Lanka, Thailand, United States as well as nine European
Countries (Austria, Belgium, France, Germany, Hungary, Italy, Spain, Sweden and The Netherlands)
together with patient organizations. UDNI Members share the strategy, general principles and best
practices to tackle undiagnosed patients, with respect to country specificities [11,12].
UDNI programs share similar organizational models, based on concentrating expertise and
capacities on undiagnosed RDs in selected medical centers, where patients can enter diagnostic
intensive hospitalization, which combine the in-depth analysis of a patient’s genotype through next
generation sequencing (NGS) techniques, sophisticated high-throughput approaches, such as RNA
sequencing and -omics technologies [13], and standardized in-depth phenotype description in order to
reach a diagnosis [14,15].
2. Getting Accurate Diagnosis through Integrated Genotype and Phenotype Analysis
In the medical literature, the term “diagnosis” has many different meanings. A “clinical diagnosis”
refers to the integrated information of findings detected by a clinician after physical examination of
the patient, an extensive medical and social history of the patient and family, and clinical findings
as reported by laboratory and instrumental tests. On the contrary, a “histological diagnosis” is the
microscopic description of tissues and cells, while a “genetic diagnosis” describes a genetic mutation,
regardless of whether the gene function is known.
The emerging era of “precision medicine” is providing a new and additional dimension to the
concept of diagnosis. Precision medicine has been defined as “treatments targeted to the needs of
individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that
distinguish a given patient from other patients with similar clinical presentations” [16]. According
to William Gahl, coordinator of the NIH Undiagnosed Diseases Program (UDP), the definition of
diagnosis that is most satisfying for the aims of precision medicine includes an understanding of
disease pathogenesis, linking genetic and clinical findings and informing prognosis and therapy [14].
2.1. Deep Genotyping
With regard to genotyping, Next Generation Sequencing (NGS) is increasingly being applied
in clinical diagnosis, to identify genetic variations associated with disease, determine fusion genes
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and detect pathogens on patient samples. Unlike previous diagnostic sequencing, in a single test,
NGS can deliver a full qualitative and quantitative analysis of the DNA or RNA sequences within
a sample, thereby holding the promise of improved diagnosis. Moreover, the use of these advanced
methodologies has accelerated the pace of discovery by enabling hypothesis-free approaches [17,18].
However, the application and analysis of NGS data and the interpretation of variants of unknown
clinical significance (VUS) remain a major challenge in diagnostics, particularly as resources for
functional studies enabling pathogenic validation are limited. The development of high-throughput
models of disease that use patient-derived material may help to clarify the implications of VUS.
Furthermore, sharing of VUS data among institutions is essential to identify overlapping results and
determine the pathogenic significance of these variants.
2.2. Deep Phenotyping
Deep phenotyping has been defined as “the precise and comprehensive analysis of phenotypic
abnormalities in which the individual components of the phenotype are observed and described,
often for the purposes of scientific examination of human disease” [19,20].
It has been reported that in highly detailed phenotyped RD cohorts, the diagnostic yield of
NGS approaches 40%, while with less specific phenotypes, the rate of diagnostic success is far
smaller [21]. Importantly, phenotype data are useful for identifying disease models and underlying
disease mechanisms according to standardized terminologies and ontologies, with annotations and
links to other information [22].
There are several ontologies that are currently being applied to the study of human diseases [23,24].
Most projects on undiagnosed RDs (e.g., the US National Institutes of Health Undiagnosed Diseases
Program, Care4Rare Canada and Australia, EURenOmics, NEUrOmics, RD-Connect, the International
Standards for Cytogenomic Arrays Consortium, national or regional undiagnosed disease programmes)
use the Human Phenotype Ontology (HPO), a comprehensive hierarchy of approximately 11,000 standard
terms, most of them with detailed definitions and alternative names [25,26].
The HPO is a core component of the Monarch Initiative, an NIH-supported collaborative, open
science effort that aims to semantically integrate genotype–phenotype data from many species and
sources in order to support precision medicine, disease modeling, and mechanistic exploration [27].
The HPO does not describe individual disease entities but, rather, the phenotypic abnormalities
associated with them, which may be shared between other RDs or more common conditions.
The computable sets of HPO terms or “phenotypic profiles” of individual patients allow imperfect
matching against the phenotypic profiles of known diseases and model organisms. This matching is useful
for differential diagnosis, and is based on proximity of terms in the hierarchy and term specificity [28].
In order to increase specificity of a patient phenotypic profile, the Monarch initiative has developed
Guidelines on “How to annotate a patient’s phenotypic profile” [29] and an annotation sufficiency
meter web service, an algorithm which allows the evaluation of a patient’s phenotype description for
specificity and completeness by rating it from one to five stars.
The Guidelines recommend that the set of phenotypes chosen for the annotation be limited to
those features that are abnormal, that they be as specific as possible, and represent the most salient
and important observed traits. The description should include onset and longitudinal observation,
utilize phenotype negation (the traits that were expected to be found but not observed), and make
quantitative specifications (e.g., levels of abnormality of laboratory results).
Some HPO based tools have been developed to be used by clinicians, to assist them in the
diagnosis of patients. These tools allow automatic extraction of HPO concepts from free text in routine
clinical activity (i.e., the software Patient Archive [30]); producing ranked lists of possible diagnoses
linked to patient’s phenotypic traits that can be further examined (i.e., Phenotips [31]); analyzing the
entered data, and providing Online Mendelian Inheritance in Man (OMIM) links to likely disorders
(i.e., Phenomizer [32]).
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Such tools offer valid support in the quest for a diagnosis, especially for the “not yet diagnosed”
patients, whose disease has already been characterized.
When, despite all efforts, the case remains unsolved or SWAN, there are several matchmaking
platforms aimed at identifying additional unrelated persons with pathogenic variant(s) in the same
gene and an overlapping phenotype, in order to narrow the number of candidate genes associated with
a particular phenotype. Currently there are 21 research projects and 25 tools using HPO terms, such as
international rare disease organizations, registries, clinical labs, biomedical resources, and clinical
software tools and, to increase the granularity and coverage of the HPO across all RDs, the ontology is
being developed in collaboration with RD experts in many different domains [26].
3. Genomics Matchmaking
The current approach to diagnostic research on RDs described above is proving to be very fruitful
as, according to the Orphanet database, since 2010 up to March 2017 more than 600 new RDs have
been described and about 3600 genes have been identified as linked to RDs [33].
On this note the “International Rare Diseases Research Consortium” (IRDiRC)’s 2020 goal for the
development of 200 new therapies was achieved in early 2017, 3 years ahead of schedule, and has
recently published its next ambitious goal for 2017–2027. That is to enable all people presenting with
a suspected RD to be diagnosed within one year, if the disorder is known in the medical literature,
and to signpost patients with unknown disorders to enter a globally coordinated diagnostic and
research pipeline [34].
There are many initiatives at both the national and international level that contribute to
IRDiRC’s goal, and many of them have developed systems and tools that enable data sharing across
multiple sources.
Matchmaking platforms creating repositories of undiagnosed cases through the collection and
comparison of genotypic and phenotypic data based on the HPO or other ontologies are being
developed by Universities, medical centers, and research institutions [35–38].
For example, FORGE and Care4Rare Canada projects, the US NIH Undiagnosed Diseases Program,
the EU Neuromics and ANDDIrare projects and several UDNI partners are using the portal for
phenotypic and genotypic matchmaking of patients with RDs Phenomecentral [37].
Western Australia Health’s Undiagnosed Diseases Program (UDP-WA) is collecting and treating
data through the HPO based software Patient Archive [30] while the Japanese Initiative on Rare
and Undiagnosed Diseases (IRUD) of the Agency for Medical Research and Development (AMED),
has developed its platform, IRUD Exchange, based on the Patient Archive model [39].
The interoperability of all these systems will enable increased analytical power to help solve
intractable diseases but, to do this, they themselves need to be connected.
Matchmaker Exchange (MME) (http://www.matchmakerexchange.org/) is a project supported by
the Global Alliance for Genomics and Health (http://genomicsandhealth.org/), the International Rare
Disease Research Consortium (http://www.irdirc.org/), and ClinGen (http://clinicalgenome.org/)
and represents the largest effort of integration amongst different resources for RDs [40].
It was launched to provide a robust and systematic approach to rare disease gene discovery
through the creation of a federated network connecting databases of genotypes and rare phenotypes
using a common application programming interface (API).
MME enables searches inside multiple databases by one single query without having to separately
query all services. Resources are integrated in a federated system where each database is autonomous
regarding its own data schema and maintains ongoing control of its own data.
Matchmaker Exchange can also serve as a paradigm for a wide range of pattern matching
services, i.e., beyond genetic mutations and phenotypes only, when generalizing its requirement for
standardized data. Many patient or disease data collections contain substantial amounts of data that
cannot be directly classified as human phenotypes. Their standardization, for instance as part of
a FAIRification procedure [41], will create a wide range of options for discovering diagnostic markers.
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4. Ethical, Legal and Social Issues in Genomics Matchmaking
The current approach to diagnostic research on RDs, based on the combination of -omics data
with phenotype data and international sharing of this information, carries benefits for both RD patients,
who increase their chance to get an accurate diagnosis, and researchers who have the opportunity
to compare their observations with colleagues at an international level and gain new insights about
mechanisms of disease.
However, the wide international sharing of patients’ data carries foreseen and unforeseen risks
for patients. For example, the risk of personal data leakage, misuse of data, direct use of data for
purposes not related with the aim of research, re-identifications, indirect diagnosis of family members
and children, and invasion of the right (not) to know.
There are ethical concerns that need to be addressed, and values to be taken into account include,
but are not limited to patient autonomy, beneficence, non-maleficence, justice, solidarity and reciprocity,
which must be respected and promoted, and, at the same time, balanced among each other (Table 1).
Table 1. Values to be considered while collecting and sharing patients’ data in matchmaking databases.
Value at Stake Actions Required Interests to Be Balanced
Respect for patient autonomy
Involve patients in the diagnostic process,
provide adequate information and
alternatives
Avoid information overload
Respect the right not to know
Take into account patient self-reported
phenotype (the patient knows best the
frequency, type and intensity of
his/her symptoms)
Preserve scientific value, check correctness
of patient assertions
Allow a role in the decisions regarding the
level of visibility and “matchability” in
matchmaking platforms
Promote the ability of other patients to
access information in order to be
diagnosed as well
Protect patients from excessive enthusiasm
and possible pressure by peers
Allow a role in the decision whether to be
informed or not about new findings as
they emerge
Evaluate scientific value of the information
Evaluate the risk/benefit ratio (including
psychological harm)
Respect the right not to know
Beneficence
Maximize the potential of diagnosing by
widening access to NGS techniques and
potentiating matchmaking platforms
(produce more data, make data interoperable
and accessible worldwide in
controlled settings)
Protect patient confidentiality
Define criteria for deciding which patients
should be prioritized for NGS
Justify costs
Offer patients adequate genetic counselling to
maximize benefits of the results and avoid
potential harms deriving from
misinterpretations of genetic data
Justify costs
Non-maleficence
Protect patient confidentiality
Do not create anxiety
Do not raise wrong expectation or false hope
Promote potentially beneficial research
Justice
Balance access to healthcare resources for
all patients
Take into account the balance cost/benefits
with regard to:
• use of sequencing techniques
• providing genetic counselling
to patients
• managing and communicating new
findings as they emerge
Provide greater access for RD patients that
face more difficulties in getting
diagnosed (beneficence)
Do not provide information to patients if
genetic counselling is not available,
especially if the information may generate
anxiety (non-maleficence/autonomy)
Solidarity among patients Make patients’ genotype and phenotype dataavailable in order to find matches
Protect patient privacy and integrity
Respect patient decisions
Researchers reciprocity with patients Make cases accessible in accordance to thedesire of patients
Preserve researchers’ capacity to stay
competitive and be able to publish results
Undiagnosed patients are usually highly motivated to participate in their own diagnostic process.
Involvement commonly includes literature searches, an interest in individual cases which may as yet be
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unpublished and the undertaking of individual initiatives throughout social media, hence increasing
awareness about their genotype and phenotype characteristics [42].
Patients are also keen to participate in biobank and registry based research, matchmaking
databases [43–45] and are often actively contributing to starting dedicated programs for undiagnosed
diseases, as in the experience of the UDNI [11].
Here we propose that, in order to mitigate the risks of RD diagnostic research, besides the most
“traditional” protections for research participants, like the informed consent of participants [46] and
the review of research projects by Institutional Review Boards (IRBs) or Research Ethics Committees
(RECs), and Data access Committees, patient involvement be maximized in the diagnostic process,
in particular by offering patients the opportunity to (Box 1):
Box 1. Patient involvement in the search for a diagnosis.
(1) Actively participate in the description of their phenotype and review the description that is made by
professionals; or contribute to the description of their phenotype to then be validated by clinicians or
specifically trained experts (especially regarding the correct use of the terminology/recognized ontology);
(2) Choose the level of visibility of their profile in matchmaking databases (e.g., private for clinicians, available
to a closed community of researchers or public);
(3) Express their preferences regarding return of new findings, in particular regarding the level of significance
a VUS should have in order to be considered relevant to them.
4.1. Patient Involvement in Phenotype Description
The first request, patient participation to phenotype description, is motivated by the possibility
that clinicians and patients consider different phenotypic traits as more or less relevant for diagnosis
in a patient’s phenotype, especially when a patient is suffering from “medically unexplained
symptoms” [47].
The concepts of “illness” and “disease” describe the different perspectives from which patients
and doctors may look at the same phenomenon. “Illness” is defined by the ill health as it is experienced
by the patient, while “disease” defines the condition as it is diagnosed by the physician following
the results of medical examinations, tests and investigations, according to standardized diagnostic
codes [48].
In the translation from “illness” to “disease”, a practitioner may filter the information provided by
the patient according to the relevance s/he attributes to certain signs or symptoms for their coherence
with a predefined hypothesis.
The role of a physician’s hypothesis, also known as clinical reasoning, is indeed fundamental
in the diagnostic process, since it provides a framework to organize the information gathered and to
actively search for additional investigations.
However, a physician might dismiss phenotypic features that are not coherent with the main
hypothesis but are relevant to the patient for diagnosis. Therefore, the patient should be entitled to
review his/her phenotype description and eventually notify the physician if s/he feels that relevant
phenotypic traits are missing or different from what is reported.
The Monarch Initiative has translated phenotype descriptions into plain language without
clinical terms unfamiliar to patients [28]. It has already developed a layer of 5000 corresponding
terms understandable for patients, thus enabling patients to actively contribute to their
phenotype description.
Patient involvement will enable the scientific community to extend ontologies, including HPO
terms, with more precise terms. As a result, terms would include more subtle auditory, visual,
and sensory traits identified by the patient community [45].
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4.2. Patient Involvement in Establishing Privacy Settings
Regulations focus on security of handling data (IT security measures) and on anonymity. However,
this may not be the primary concern for undiagnosed RD patients. While protecting confidentiality
and applying all the possible measures to ensure proper access is still critical [49], other preoccupations
may be more important in the search for a diagnosis [50].
For the purposes of increasing the number of matches that are currently possible with the use of
existing platforms, it would be ideal if the described cases were routinely made available to a wider,
albeit closed, community of researchers, if not completely public, in accordance with national privacy
regulations and with the preferences of the patient.
For a number of reasons, including the wish to protect the patient’s privacy or the wish to be
the first to identify and publish causative or implicated gene(s), a researcher may decide to keep the
patient record “private” or to share it with a limited number of researchers thus limiting the possibility
to find matches in wider matchmaking networks.
While a researcher can be aware of the risks deriving from wider data sharing, the discussion
should always be pursued with the patient.
Acknowledging a patient’s will may provide a balance between unnecessary paternalism and
undue liberalism in dealing with undiagnosed patients’ data.
4.3. Patient Involvement in Decisions about Communicating Secondary Findings
The third request is that undiagnosed patients should be offered appropriate genetic counselling,
allowing them to have an educated insight into the significance of particular variants, and hence be
able to decide which specific variants should be communicated as a “secondary finding”.
According to the American Society of Human Genetics, genetic counselling is a “communication
process which involves an attempt by one or more qualified persons to help the individual or family
to: (1) comprehend the medical facts, including the diagnosis, probable course of the disorder,
and the available management; (2) appreciate the way heredity contributes to the disorder ( . . . .);
(3) understand the alternatives for dealing with the risk of occurrence; (4) choose the course of action
which seems to them appropriate ( . . . .); (5) make the best possible adjustment to the disorder ( . . . .)
and/or the risk of recurrence of that disorder” [51].
With the use of NGS techniques, there is a greatly increased likelihood of identification of variants
which are not directly linked with the known/expressed phenotype. While diagnostic variants rely on
the fact that patients are aware of possible variants and are interested to determine the specific causative
variant, secondary variants may be revealed unexpectedly carrying unwanted implications that may
add to an already delicate situation. It is also important to note that providing adequate information in
the consent process may be a challenge since counselling cannot be provided preemptively on a great
number of variants.
To deal with this complexity, models of multistage consent have been proposed for the return
of findings [52,53]. These models foresee that patients can provide a general answer for being
re-contacted and delay the final decision until more information is available for better informing
the decisional process.
Along with the consent models, another decisional process includes deciding whether a patient
should be made aware of a particular variant. It has been suggested that results originating from
sequencing (whether related to the original research question or not) that are “actionable” should be
returned to participants, as they have acceptable clinical validity and an important impact on patients’
health (for example BRCA1 or BRCA2 mutations) [54]. However, the threshold and definition of
“acceptable” clinical validity and impact are highly variable, and a source of great controversy among
experts. This consideration applies also to the “actionability” concept that falls among the criteria for
returning results. In fact, a result can be considered to have clinical utility when actions can be taken
based on its outcome and, according to different interpretations. Actions may be limited to therapeutic
and preventive measures or it may extend to include reproductive choices and other decisions that
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are relevant for the patient or family like, for example, living arrangements. In addition, it must be
remembered that clinical utility has different meanings in different health care contexts, in which
different preventive or therapeutic interventions can be offered.
For an undiagnosed patient, other priority criteria may apply: the possibility to actively search
for information on the new variant and eventually contact other carriers to organize common actions
in order to raise awareness within the scientific community makes the information equally actionable.
Pioneering projects and programs dealing with undiagnosed diseases have reported their
experiences regarding returning results to participants. For example, one study performed by the
Canadian FORGE project, revealed that, in general, parents want to receive as much information
about their child’s health as possible. In this case, the benefits of receiving all incidental findings and
expanding their knowledge base outweighs the potential harm [55]. Thus, undiagnosed patients are
usually willing to be informed about new findings, independently from the immediate clinical utility.
A cost benefit ratio still needs to be applied in each individual case. For those results not related
to the specific RD under study, a possibility for opportunistic screening arises, given that the entire
variant sequence is produced anyway. This is a form of screening where, as the term “opportunistic”
suggests, screening for other genes is conducted because it is convenient [56]. Regarding these results,
RD patients should hold the same right to access results as the general population [57,58].
5. On the Appropriateness of Prescribing NGS Techniques for Undiagnosed Cases
The great potential of NGS techniques generates a great deal of hope among undiagnosed patients.
Indeed, to the point that SWAN Europe, the European coalition of associations specifically dedicated
to undiagnosed patients, lists “facilitating access to genomic technologies for families within the
undiagnosed community” among its main objectives [59].
The optimal timing for Whole Exome Sequencing (WES) in the diagnostic process is still unclear,
whether it should be at the first medical encounter after a clinical evaluation where a significant genetic
heterogeneity is evident, or after having performed first tier gene tests, or alternatively towards the
end of the diagnostic odyssey when extensive and possibly invasive tests have already occurred [60].
Indeed, the indication for WES becomes clear once no pathogenic variant is detected in the first five
candidate genes in the possible differential diagnoses. However, it is of note to emphasize the waiting
time between each individual test result and both the emotional and financial cost to the patient for
each recurrent clinic visit.
NGS, and in particular WES, has proved to have a high diagnostic utility and to be cost effective
in undiagnosed patients. It allows to the dramatic reduction in both the number of tests and the time
required to arrive at an accurate diagnosis, thus reducing the significant financial and psychological
burdens associated with prolonged investigation [61–64].
However, currently the waiting list for specialist referral is the rate-limiting process in the
determination of a diagnosis. This not due to technological issues, but rather due to shortage of
qualified experts for the analysis of the sequencing results. Therefore, there is a need to increase
capabilities and training of experts to analyze these findings, and hence streamline patients’ diagnostic
pathways. The availability of suitably qualified clinicians varies greatly from country to country.
Moreover, though the cost of NGS testing is falling dramatically, with the expected increase in use of
genome and exome sequencing, the cost of storing this huge data may become a critical issue.
Based on the UK number and extrapolating to the European population, SWAN Europe have
estimated that more than 65,000 children with an unnamed syndrome are born in Europe each year [59].
It is likely that by summing up the number of “yet to be diagnosed” and “SWAN” patients, the
request to perform NGS techniques in all patients who are lacking accurate diagnosis will become
evident to healthcare systems and competent authorities in the near future.
Thus, questions remain regarding which undiagnosed patients should be prioritized for NGS
analysis. Who should interpret the results and by what criteria? Who should return these results,
and which resources are available or need to be developed to this aim? Answers would highlight as
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to where the involvement of medical doctors (MD) is needed, a potential bottleneck and thus, issue.
It appears reasonable to envision a situation where experts trained in modern data interpretation aid
MDs and patients, thus reducing the demand on MDs in the overall process, consequently reducing
the time taken to reach the correct diagnosis.
A model to take into consideration is the NIH UDP, where the decision whether to perform
or not NGS is taken on a case-by-case basis with the involvement of multiple RD experts, largely
through consultations during UDP admissions. The program utilizes massive parallel sequencing
from phenotype informed genetic testing and biochemical and radiologic investigations and molecular
analyses to reach a diagnosis [65,66].
Modifications of this model are being used by other UDP programs worldwide [11,67,68] and
modified taking into account the resources and organization of healthcare services in each country.
Despite this, the US UDP model has also been criticized for being successful in only a small proportion
of the patients evaluated, for not necessarily resulting in the development of a management plan, and
for being funded by the NIH “without any consideration of cost” [69].
6. Solidarity and Reciprocity among RD Patients and Researchers
The availability of new tools, such as NGS, deep standardized phenotyping, and matchmaking
databases enable physicians, researchers, and patients to find matches with similar patients and
discover patterns that can lead to appropriate and targeted diagnostic tests.
Besides, the current trend to standardize phenotype description and other types of observations by
using ontologies carries the potential to improve communication between patients and clinicians who
can both contribute to building and applying a common standardized vocabulary. Importantly,
unambiguous coding of data in terms of machine readable ontologies opens new gateways for
computational support.
However, there may still be ethical, legal constraints and socio-cultural barriers to data sharing
that limit the capacity to fully exploit the potential of available information and the size of matchmaking
networks, thus limiting the possibility to identify matches.
According to Boycott et al., it takes approximately 2–3 years to identify an additional unrelated
individual with a pathogenic mutation in the same gene after publication of a single patient or family.
The number of cases with candidate genes (e.g., containing deleterious-appearing genetic variation)
that are unpublished and/or in inaccessible “silos” worldwide, is estimated to be more than 1000 [2].
One of the main reasons researchers may not share patients’ data is the possibility that patient
privacy may not receive adequate protection at the international level, or that the informed consent
documents and IRB/REC opinions would not permit data sharing for the cases of interest.
Solutions are under study to overcome privacy problems and automate access to patient data
with due respect of ELSI requirements.
In particular, an IRDiRC/Global Alliance for Genomics and Health (GA4GH) working group
is currently investigating privacy-preserving record linking to overcome the problem of patient
identification while still enabling data from the same patient in multiple data sources to be
combined [70]. Two other initiatives, the Consent Codes model [71] and the Automatable Discovery
and Access Matrix (ADA-M) [72], are working to enable a computable representation of consent
codes and of legal and institutional-based permissions and restrictions associated with research and
clinical records (i.e., IRB/REC opinions, DAC decisions, etc.) to facilitate automated access to existing
resources. Researchers’ may also withhold patient data with the worry that it would be used without
appropriate attribution [2].
The development of solutions to overcome this “trust barrier” are ongoing. Currently, it has
been suggested to implement federated models among matchmaking databases, where databases are
connected through APIs inside a network (i.e., in the MME), and each database supports queries of
other databases whilst keeping control over its own data. A federated model will enable researchers
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to keep control over their cases and participate in DAC deliberations regarding the question of data
sharing, including, for what purposes and under what conditions.
Additionally, efforts are underway to study mechanisms that would allow the traceability of
registered users and of uploaded cases, logging how they are utilized and by whom.
Registered access will address different categories of potential data users (researchers, clinical
care professionals, and patients), as well as different levels of data depending on their identifiability
and sensitivity [73].
The propensity of researchers not to share patients’ data might not always be the preferred option
by patients. As a result, patient-led platform have been created, enabling patients to take direct
responsibility in the decision over privacy settings and hence what information they would like to
share and with whom.
In patient led matchmaking databases, patients can access larger networks, disseminate
information through other channels, including social media and patient associations, and provide
detailed sets of phenotypic and genotypic data, often longitudinal in nature, even without expert
mediation [45].
There is growing recognition that patients led research (PLR) can generate useful information
for researchers. However, it has also been questioned for not being subject to ethical oversight and
for methodological limitations including bias, self-selection, and problems with self-reporting of
symptoms or phenotypic data [74–76]. The risk of engendering duplications and poor coordination of
efforts with increased “false matches” may be a side effect of the multiplication of different genomics
matchmaking databases [45].
To avoid this, collaboration between patients and researchers is key, thus maximizing the potential
to discover real matches while minimizing informational risks for patients, ultimately improving
general RD patient outcomes.
In this “new model” of clinical diagnostics, families, patients, and scientists work jointly to find
new patients, confirm or refute hypotheses and exchange clinical information [42].
If these conditions are met, it will be possible to increase the capacity for data sharing far beyond
what is permissible today, providing that patients can to control the type and level of sharing.
7. Conclusions
As its ultimate goal for 2017–2027, the IRDIRC recently proposed to enable all patients presenting
with a suspected RD to be diagnosed within one year if the disorder is known, and to that all currently
unsolved cases enter a globally coordinated diagnostic and research pipeline [34].
For an RD patient, a diagnosis can be the key to unlocking access to effective medical and social
care as well as to targeted treatment. Even if no treatment is available, the right diagnosis, including
the accompanying prognostic information, still empowers patients to plan their future.
Achieving a means of diagnosing all RGDs will allow patients and families to access genetic
counselling, obtain better prognostication, and identify specific health risks for the individual.
Unnecessary or harmful diagnostic interventions and/or treatments will be avoided, improving
the patient experience while simultaneously decreasing the burden of cost on healthcare systems.
In an increasing number of patients, effective drug treatment is available once the exact diagnosis
has been established [2]. When no treatment is available patients may be invited to participate in
research cohorts for clinical trials, stratified by genes or other clinical characteristics, with the possibility
to develop new targeted drugs.
The new vision of the IRDiRC underlines the need to move from diagnosis to treatment,
consequently enabling all people living with a RD to receive an accurate diagnosis, effective care,
and available therapy within one year of coming to medical attention.
To this aim “methodologies will be developed to assess the impact of diagnoses and therapies on
RD patients” (point 3).
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Despite huge initial costs required for the setup of dedicated programs for undiagnosed patients,
achievements will likely not only benefit those within the RD community but also have positive fallouts
for the diagnosis and treatment of more common diseases and thus the wide global population.
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